Safety findings align with incretin-class tolerability profiles: higher rates of gastrointestinal events (nausea, diarrhea, constipation, vomiting) and more frequent reports of dysesthesia were observed in active arms than placebo, and adverse-eventrelated discontinuations were dose-related.
Targeted therapy with signal transduction inhibitors (dabrafenib, trametinib, vemurafenib, cobimetinib, encorafenib, binimetinib)
Some other medications can lead to low levels of vitamin B12 in your body
No evidence suggests that optimizing b12 status accelerates weight loss beyond what would occur with adequate nutrition overall
Yes, semaglutide can cause gastrointestinal troubles, which include constipation as well
Moderate Thinning (Norwood 3-4 / Ludwig 2) Significant miniaturization with visible scalp